InvestorsHub Logo
Followers 789
Posts 118175
Boards Moderated 19
Alias Born 09/05/2002

Re: None

Friday, 07/29/2022 2:07:50 PM

Friday, July 29, 2022 2:07:50 PM

Post# of 1161
Opdivo/Yervoy misses DFS primary endpoint in adjuvant RCC:

This result is from Part A of the CHECKMATE-914 study, where Opdivo/Yervoy was compared to placebo. Part B of the same study, which compares Opdivo monotherapy to placebo, is still in progress.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News